Guest article - 15/04/2013 Varied and multi-facetted – life and research in Nanjing Joachim Koepff spent six months in Nanjing from June to November 2012 doing practical training at the College for Biotechnology and Pharmaceutical Engineering. Here he recounts his experiences in China and his thoughts about the Baden-Württemberg Ministry of Science Research and the Arts scholarship that makes such short-term research stays at a Chinese research institution possible.https://www.gesundheitsindustrie-bw.de/en/article/news/varied-and-multi-facetted-life-and-research-in-nanjing
Article - 14/09/2009 SensScreen Technologies: Magnetic separation to conquer biotechnological areas of application In terms of protein purification, the biopharmaceutical industry is increasingly reaching its technical and economic limits. The currently used chromatography procedures are expensive, time-consuming and associated with high product losses due to the large number of individual processing steps involved. Special magnetic microparticles, such as those developed by the chemist Dr. Jochen F. Peter with his recently established company SensScreen…https://www.gesundheitsindustrie-bw.de/en/article/news/sensscreen-technologies-magnetic-separation-to-conquer-biotechnological-areas-of-application
Article - 09/02/2009 Bodo Philipp – the discovery of the general principles of bacterial interaction Dr. Bodo Philipp from the University of Constance specifically focuses on ecologically relevant activities of bacteria for example cell-cell interactions. His findings could prove effective in removing bacteria from areas where high levels of hygiene are required thereby making it possible to prevent life-threatening bacterial infectious diseases. Dr. Bodo Philipp uses the much feared Pseudomonas aeruginosa bacteria as model organisms for his…https://www.gesundheitsindustrie-bw.de/en/article/news/bodo-philipp-the-discovery-of-the-general-principles-of-bacterial-interaction
Article - 16/09/2013 Infrared light as an indicator of wine quality Guaranteeing the quality of wines is becoming increasingly important so that they are able to compete in the international market. However, the quality control methods currently used are often rather time-consuming and costly. In addition, it is difficult to detect microbial grape contaminations that might jeopardise the quality of the wines. Researchers at the National Training and Research Institute for Viticulture and Horticulture in…https://www.gesundheitsindustrie-bw.de/en/article/news/infrared-light-as-an-indicator-of-wine-quality
Article - 12/01/2015 Bionic chemistry: developing tailor-made functional units for bacterial cells Dr. Stefan Schiller from the Center for Biological Systems Analysis (ZBSA) at the University of Freiburg combines synthetic biology and synthetic chemistry concepts in order to equip bacterial cells with organelle-like compartments. He has countless biotechnological applications in mind. In 2014, Schiller received the research prize “Next Generation of Biotechnological Methods – Biotechnology 2020+”. The prize is awarded every two years and…https://www.gesundheitsindustrie-bw.de/en/article/news/bionic-chemistry-developing-tailor-made-functional-units-for-bacterial-cells
Article - 19/03/2012 Protein aggregation: when proximity becomes dangerous The aggregation of proteins in the human body might have severe medical consequences, as is the case with Alzheimer’s disease, for example. A less known fact is that the biopharmaceutical industry is also faced with the biological phenomenon of protein aggregation and is working on preventive measures. https://www.gesundheitsindustrie-bw.de/en/article/news/protein-aggregation-when-proximity-becomes-dangerous
Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015 Biametrics GmbH concludes financing round with 3.1 Million Euro Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biametrics-gmbh-concludes-financing-round-with-31-million-euro
Article - 02/06/2017 SÜDPACK: a great example of biotech as a cross-sectoral technology SÜDPACK Verpackungen is a qualified supplier of plastic films to the biopharmaceutical industry. The company is the leading European manufacturer of packaging products for the food industry and also offers its expertise to the biopharmaceutical industry. In 2011, SÜDPACK created an exclusive cooperation partnership with Sartorius Stedim Biotech, a global technology provider for the pharmaceutical biotech industry, which has now been extended…https://www.gesundheitsindustrie-bw.de/en/article/news/suedpack-a-great-example-of-biotech-as-a-cross-sectoral-technology
Article - 20/11/2011 Can probiotic lactic acid bacteria protect the intestines against pathogens? Nutrition scientists from the Max Rubner-Institut MRI in Karlsruhe are investigating how human pathogens and probiotic bacterial strains interact with each other in the human gastrointestinal tract. Are probiotic bacteria in yoghurt or in pickled vegetables for example able to reduce the health risk posed by pathogenic bacteria?https://www.gesundheitsindustrie-bw.de/en/article/news/can-probiotic-lactic-acid-bacteria-protect-the-intestines-against-pathogens
Dossier - 24/04/2008 Contract manufacture: the order books remain full The market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 2005 to approx. 150 until 2010.https://www.gesundheitsindustrie-bw.de/en/article/dossier/contract-manufacture-the-order-books-remain-full
Guest article - 07/04/2014 Experience report from Nanjing Marcel Loewert, who is studying bioengineering (M. Sc.) at the Karlsruhe Institute of Technology (KIT), was awarded a China scholarship from the Baden-Württemberg Ministry of Science, Research and the Arts to spend five months at the College of Biotechnology and Pharmaceutical Engineering in Nanjing, capital and communications centre in China’s Jiangsu Province. Here Marcel reports about the experiences he made during his five-month stay in…https://www.gesundheitsindustrie-bw.de/en/article/news/experience-report-from-nanjing
Article - 29/07/2009 Protein crystallisation: an attractive alternative to protein purification The production of pure crystals is a method that is normally used for the determination of the spatial structure of a protein using X-ray defraction. Crystalline proteins have a very regular structure, meaning that contaminations can to a large extent be excluded. Therefore, protein crystals only contain a small number of foreign substances, which makes them a lot more stable in solution than proteins are. Due to the aforementioned properties,…https://www.gesundheitsindustrie-bw.de/en/article/news/protein-crystallisation-an-attractive-alternative-to-protein-purification
Dossier - 02/05/2011 Molecular bionics – inspirations from the microworld for the macroworld Knowledge about the molecular organisation of structural and functional biological properties has led to the establishment of a new field of research molecular bionics. Everything that can be learnt from the macromolecular observation of interesting natural phenomena is complemented in this field by observations on the smallest i.e. molecular level. Processes and materials that have been optimised in the course of evolution are thus able to…https://www.gesundheitsindustrie-bw.de/en/article/dossier/molecular-bionics-inspirations-from-the-microworld-for-the-macroworld
Article - 19/03/2012 Soil bacteria to produce new antibiotics An ever-growing number of genomes of soil bacteria of the genus Streptomyces are being sequenced. Using a method known as “genome mining”, researchers at the University of Tübingen are working on the identification of gene clusters that have the potential to be used in industrial biotechnology for the production of new antibiotics and other pharmaceutically active substances. To achieve this, the biosynthesis gene clusters are integrated into…https://www.gesundheitsindustrie-bw.de/en/article/news/soil-bacteria-to-produce-new-antibiotics
Press release - 18/08/2008 One third of all biopharmaceuticals get a "sugar coating" More than 50 of recombinant proteins are altered while they are being synthesized in the cells sometimes once and sometimes several times. Experts call these alterations post-translational modifications. https://www.gesundheitsindustrie-bw.de/en/article/news/one-third-of-all-biopharmaceuticals-get-a-sugar-coating
Article - 14/05/2012 Biogas and sustainability The German Renewable Energy Sources Act (EEG) has led to a considerable increase in the use of biogas in Germany. However, increasing biogas production must make ecological sense and not generate conflict with the sustainability objectives of environmental conservation schemes. There must therefore be a careful consideration of the overall conditions. An analysis of the ecological impact of the generation and use of biogas in Germany taking into…https://www.gesundheitsindustrie-bw.de/en/article/news/biogas-and-sustainability
Dossier - 16/07/2009 Patents – the exploitations of inventions in the life sciences According to statistics from the European Patent Office a total of 1065 biotechnological patents were filed in 2007 by inventors based in Germany. This puts Germany second behind the USA. In the coming years experts expect that a much larger number of biotech patents will be filed. For life sciences inventors the registration of patents quite often represents a real challenge. People entering the world of patents and licences are faced with a…https://www.gesundheitsindustrie-bw.de/en/article/dossier/patents-the-exploitations-of-inventions-in-the-life-sciences
Article - 10/01/2011 Review: What does the cell factory of the future look like? A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production. https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
Article - 21/11/2009 “Big companies do not specialise enough” Dr. Aziz Cayli worked for many years for big biotechnology and pharmaceutical companies. In 2005 he took the path of independence and set up the company CELLCA based in Laupheim Germany. Here Cayli talks to Christoph Bächtle about the fact that having the right partners plays a decisive role in establishing a company.https://www.gesundheitsindustrie-bw.de/en/article/news/big-companies-do-not-specialise-enough
Article - 30/03/2009 More than milk and business Although there is very little difference between the biotechnological methods used in the dairy industry and those used in other industries nevertheless biotechnology operates differently here. Why can certain goals sometimes be reached more effectively without academic research?https://www.gesundheitsindustrie-bw.de/en/article/news/more-than-milk-and-business
Article - 12/03/2013 Science to business – exit strategies for biotech companies The two directors of the consultancy firm LSCN Ltd. Dr. Alrik Koppenhöfer and Dr. Volker Ungermann explain the key issues involved in MA negotiations and licensing deals and how LSCN supports biotechnology companies and strategic investors in reaching their goals. Both managers agree that a good dose of realism is necessary. https://www.gesundheitsindustrie-bw.de/en/article/news/science-to-business-exit-strategies-for-biotech-companies